Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new small-molecule medicines.
Incyte will choose the initial collaboration targets for the partnership. It secured the exclusive rights for the clinical development and commercialisation of these products.
The collaboration will initially focus on two targets. For a predetermined fee, Incyte retains the option to nominate an additional target.
Genesis will obtain a $30m upfront payment. For each target, the company could obtain up to $295m in development, regulatory and commercial milestone payments, subject to the achievement of all milestones.
The company is additionally eligible for tiered royalties on sales of any approved collaboration products.
Leveraging Genesis Exploration of Molecular Space (GEMS), the AI platform of Genesis, the partnership is set to discover and optimise the small-molecule compounds required for the targets.
Genesis Therapeutics founder and CEO Evan Feinberg stated: “AI has the potential to redefine how we discover small-molecule medicines, and our team is at the forefront of this revolution.
“We are pleased to establish this world-class partnership to combine our GEMS AI platform with Incyte’s deep expertise and track record in drug discovery and development, with the shared goal of advancing critical treatments for patients with severe diseases.”
Genesis has a fully integrated lab in San Diego, US, and is focused on integrating AI methods such as language models, diffusion models and physical simulation into its GEMS platform.
This integration facilitates the generation and optimisation of molecules for complex targets.
Having raised more than $300m from technology, AI-focused and life science investors, the company is building a therapeutics pipeline across high-impact targets.
The collaboration follows Incyte’s strategic partnership with AbCellera in September 2023, which focused on the discovery and development of therapeutic antibodies in oncology.
Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
